Screening and detection of heterogenous vancomycin intermediate Staphylococcus aureus in Hospital Kuala Lumpur Malaysia, using the glycopeptide resistance detection Etest and population analysis profiling
- PMID: 24470927
- PMCID: PMC3892648
- DOI: 10.4081/idr.2012.e20
Screening and detection of heterogenous vancomycin intermediate Staphylococcus aureus in Hospital Kuala Lumpur Malaysia, using the glycopeptide resistance detection Etest and population analysis profiling
Abstract
In a 3-month study done in Hospital Kuala Lumpur (HKL), 7 out of 320 methicillin resistant Staphylococcus aureus isolates were confirmed as heterogeneous vancomycin intermediate S. aureus (hVISA) using the glycopeptide resistance detection e-test and population analysis, giving a prevalence rate of 2.19%. This is the first report of hVISA in Malaysia.
Keywords: Hospital Kuala Lumpur.; heterogenous vancomycin intermediate Staphylococcus aureus (hVISA).
Conflict of interest statement
Conflict of interest: all other authors report no conflicts of interest.
Similar articles
-
Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.J Clin Microbiol. 2011 Jan;49(1):269-74. doi: 10.1128/JCM.00914-10. Epub 2010 Oct 20. J Clin Microbiol. 2011. PMID: 20962147 Free PMC article.
-
Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.J Microbiol Immunol Infect. 2016 Oct;49(5):701-707. doi: 10.1016/j.jmii.2015.07.003. Epub 2015 Jul 31. J Microbiol Immunol Infect. 2016. PMID: 26320398
-
Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.J Microbiol Immunol Infect. 2012 Dec;45(6):435-41. doi: 10.1016/j.jmii.2012.05.004. Epub 2012 Jun 30. J Microbiol Immunol Infect. 2012. PMID: 22749725
-
Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).Intern Med J. 2005 Dec;35 Suppl 2:S136-40. doi: 10.1111/j.1444-0903.2005.00986.x. Intern Med J. 2005. PMID: 16271057 Review.
-
Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.Pharmacotherapy. 2015 Apr;35(4):424-32. doi: 10.1002/phar.1577. Pharmacotherapy. 2015. PMID: 25884530 Review.
Cited by
-
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.Sci Rep. 2020 Jul 29;10(1):12689. doi: 10.1038/s41598-020-69058-z. Sci Rep. 2020. PMID: 32728110 Free PMC article.
-
Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.PLoS One. 2015 Aug 19;10(8):e0136082. doi: 10.1371/journal.pone.0136082. eCollection 2015. PLoS One. 2015. PMID: 26287490 Free PMC article.
-
Epidemiology, mechanisms, and clinical impact of bacterial heteroresistance.NPJ Antimicrob Resist. 2025 Jan 28;3(1):7. doi: 10.1038/s44259-025-00076-5. NPJ Antimicrob Resist. 2025. PMID: 39875628 Free PMC article. Review.
-
Methicillin-Resistant Staphylococcus aureus (MRSA) Clonal Replacement in a Malaysian Teaching Hospital: Findings from an Eight-Year Interval Molecular Surveillance.Antibiotics (Basel). 2021 Mar 19;10(3):320. doi: 10.3390/antibiotics10030320. Antibiotics (Basel). 2021. PMID: 33808728 Free PMC article.
-
Staphylococcus aureus Infections in Malaysia: A Review of Antimicrobial Resistance and Characteristics of the Clinical Isolates, 1990-2017.Antibiotics (Basel). 2019 Aug 26;8(3):128. doi: 10.3390/antibiotics8030128. Antibiotics (Basel). 2019. PMID: 31454985 Free PMC article. Review.
References
-
- Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350:1670–3. - PubMed
-
- Howden BP, Davies JK, Johnson PDR, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin intermediate and heterogenous vancomycin-intermediate strains: resistant mechanism, laboratory detection and clinical implications. Clin Microbiol Rev. 2010;23:99–139. - PMC - PubMed
-
- Hanaki H, Kuwahara-Arai K, Boyel-Vavra S, et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother. 1998;42:199–209. - PubMed
-
- National surveillance of antibiotic resistance 2008. Available from: www.imr.gov.my/report/nsar.htm.
LinkOut - more resources
Full Text Sources